Health
Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI – Insight – BioSpace
Patrys Limited, a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic…
Series of preclinical studies demonstrate the therapeutic potential of PAT-DX1, a first-in-class, synthetically lethal DNA-binding antibody in primary brain cancers and brain metastases.MELBOURNE–(BUSINESS WIRE)– Patrys Limited (ASX:PAB), a therapeutic…
Continue Reading
-
General18 hours agoQantas terminal at Melbourne Airport evacuated and flights delayed due to fire
-
Business23 hours ago3 of the best ASX ETFs for beginners to buy with $1,000
-
Business22 hours agoWhy this ASX 200 tech stock could rise 20%
-
Noosa News22 hours agoToyah Cordingley’s accused killer ‘3.7 billion times more likely than not’ to have contributed to DNA sample near burial site, court told